QR Code

C014 | EFFICACY AND SAFETY OF IBRUTINIB AS SECOND-LINE TREATMENT IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: INTERIM ANALYSIS OF THE OLIMPUS STUDY

Introduction: Mantle cell lymphoma (MCL) is an incurable disease characterized by an aggressive clinical course. Ibrutinib has been approved for relapsed/refractory (R/R) MCL and rapidly became standard therapy in the second-line setting. Several studies have reported results with ibrutinib in R/R...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: C. Visco., A. Moioli, L. Arcaini, A.M. Frustaci, C. Muzi, M. Nicolosi, A. Re, G. Catania, E. Cencini, A. Chiarenza, A. Di Rocco, L. Laurenti, C. Patti, F.G. Rossi, B. Bianchi, A. Ferreri, D. Mannina, F. Meconi, P. Musto, B. Puccini, B. Casadei, S. Ferrero, M. Foglietta, S. Galimberti, M. Musso, P.R. Scalzulli, M. Spina, P.M. Stefani, F. Piazza, I. Scortechini, M.P. Simula, A. Tafuri, D. Vallisa, F. Zaja, V. Mattiello, M. Palma, A. Tedeschi, P.L. Zinzani
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Ferrata Storti Foundation 2025-09-01
Rangatū:Haematologica
Urunga tuihono:https://haematologica.org/article/view/12878
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite